Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial.

Published

Journal Article

OBJECTIVE: To investigate the acute efficacy and adverse side effects of methylphenidate (MPH) among survivors of childhood cancer [acute lymphoblastic leukemia (ALL) or brain tumor (BT)] with learning impairments. METHODS: Participants (N = 122) completed a two-day, in-clinic, double-blind, cross-over trial during which they received MPH (0.60 mg/kg of body weight) and placebo that were randomized in administration order across participants. Performance was evaluated using measures of attention, memory, and academic achievement. RESULTS: A significant MPH versus placebo effect was revealed on a measure of attention, cognitive flexibility, and processing speed (Stroop Word-Color Association Test). Male gender, older age at treatment, and higher intelligence were predictive of better medication response. No significant differences were found for number or severity of adverse side effects as a function of active medication. CONCLUSIONS: MPH shows some neurocognitive benefit and is well tolerated by the majority of children surviving ALL and BT.

Full Text

Duke Authors

Cited Authors

  • Conklin, HM; Khan, RB; Reddick, WE; Helton, S; Brown, R; Howard, SC; Bonner, M; Christensen, R; Wu, S; Xiong, X; Mulhern, RK

Published Date

  • October 2007

Published In

Volume / Issue

  • 32 / 9

Start / End Page

  • 1127 - 1139

PubMed ID

  • 17569711

Pubmed Central ID

  • 17569711

International Standard Serial Number (ISSN)

  • 0146-8693

Digital Object Identifier (DOI)

  • 10.1093/jpepsy/jsm045

Language

  • eng

Conference Location

  • United States